Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6228368,retention times,"A good separation of zimelidine and norzimelidine was obtained following derivatisation of norzimelidine with heptafluorobutyric anhydride, the retention times being 6.16 and 10.35 minutes, respectively.",Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),min,6.16,10294,DB00835,Brompheniramine
,6228368,retention times,"A good separation of zimelidine and norzimelidine was obtained following derivatisation of norzimelidine with heptafluorobutyric anhydride, the retention times being 6.16 and 10.35 minutes, respectively.",Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),min,10.35,10295,DB00835,Brompheniramine
,6228368,sensitivity,The sensitivity of the method is 5 ng/ml for zimelidine and norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),[ng] / [ml],5,10296,DB00835,Brompheniramine
,6228368,peak plasma concentration,"Zimelidine was rapidly absorbed, giving a mean peak plasma concentration of 103.9 +/- 34.8 ng/ml.",Pharmacokinetic study of zimelidine using a new GLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),[ng] / [ml],103.9,10297,DB00835,Brompheniramine
,6228368,plasma elimination half-life,The mean plasma elimination half-life was 8.4 +/- 2.0 hours for zimelidine and 19.4 +/- 3.6 hours for norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),h,8.4,10298,DB00835,Brompheniramine
,6228368,plasma elimination half-life,The mean plasma elimination half-life was 8.4 +/- 2.0 hours for zimelidine and 19.4 +/- 3.6 hours for norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),h,19.4,10299,DB00835,Brompheniramine
,528601,flow-rate,A mobile phase 20% acetonitrile in 0.0075 M phosphate buffer at a flow-rate of 2 ml/min was used for the assays of plasma and saliva samples.,"Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528601/),[ml] / [min],2,56120,DB00835,Brompheniramine
less,528601,retention volumes,The drug and internal standard were eluted at retention volumes of less than 17 ml.,"Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/528601/),ml,17,56121,DB00835,Brompheniramine
,6128358,peak serum brompheniramine concentration,The mean peak serum brompheniramine concentration of 11.6 +/- 3.0 ng/ml occurred at a mean time of 3.1 +/- 1.1 hr.,The pharmacokinetics and antihistaminic effects of brompheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128358/),[ng] / [ml],11.6,57225,DB00835,Brompheniramine
,6128358,mean time,The mean peak serum brompheniramine concentration of 11.6 +/- 3.0 ng/ml occurred at a mean time of 3.1 +/- 1.1 hr.,The pharmacokinetics and antihistaminic effects of brompheniramine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128358/),h,3.1,57226,DB00835,Brompheniramine
,6128358,serum half-life,"The mean serum half-life value was 24.9 +/- 9.3 hr, the mean clearance rate was 6.0 +/- 2.3 ml/min/kg, and the mean volume of distribution was 11.7 +/- 3.1 L/kg.",The pharmacokinetics and antihistaminic effects of brompheniramine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128358/),h,24.9,57227,DB00835,Brompheniramine
,6128358,clearance rate,"The mean serum half-life value was 24.9 +/- 9.3 hr, the mean clearance rate was 6.0 +/- 2.3 ml/min/kg, and the mean volume of distribution was 11.7 +/- 3.1 L/kg.",The pharmacokinetics and antihistaminic effects of brompheniramine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128358/),[ml] / [kg·min],6.0,57228,DB00835,Brompheniramine
,6128358,volume of distribution,"The mean serum half-life value was 24.9 +/- 9.3 hr, the mean clearance rate was 6.0 +/- 2.3 ml/min/kg, and the mean volume of distribution was 11.7 +/- 3.1 L/kg.",The pharmacokinetics and antihistaminic effects of brompheniramine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128358/),[l] / [kg],11.7,57229,DB00835,Brompheniramine
,6452803,elimination half-lives,"The mean elimination half-lives of zimelidine and norzimelidine were found to be 15 h and 35 h, respectively, which were longer than the half-lives earlier obtained in younger patients.",Zimelidine to geriatric patients: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6452803/),h,15,76169,DB00835,Brompheniramine
,6452803,elimination half-lives,"The mean elimination half-lives of zimelidine and norzimelidine were found to be 15 h and 35 h, respectively, which were longer than the half-lives earlier obtained in younger patients.",Zimelidine to geriatric patients: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6452803/),h,35,76170,DB00835,Brompheniramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB00835,Brompheniramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB00835,Brompheniramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB00835,Brompheniramine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB00835,Brompheniramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB00835,Brompheniramine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB00835,Brompheniramine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB00835,Brompheniramine
,6455297,terminal phase half-life,There was no significant difference in terminal phase half-life of zimelidine after oral (4.7 h +/- 1.3 SD) or intravenous dosing (5.1 h +/- 0.7 SD).,Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455297/),h,4.7,100513,DB00835,Brompheniramine
,6455297,terminal phase half-life,There was no significant difference in terminal phase half-life of zimelidine after oral (4.7 h +/- 1.3 SD) or intravenous dosing (5.1 h +/- 0.7 SD).,Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455297/),h,5.1,100514,DB00835,Brompheniramine
,6455297,bioavailability,"It appears that zimelidine is completely absorbed from the gastrointestinal tract and ""first-pass metabolism"" in the liver reduces the bioavailability to 50%.",Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455297/),%,50,100515,DB00835,Brompheniramine
,6455297,plasma half-life,The mean plasma half-life for norzimelidine was 22.8 h.,Pharmacokinetics of zimelidine in humans--plasma levels and urinary excretion of zimelidine and norzimelidine after intravenous and oral administration of zimelidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455297/),h,22.8,100516,DB00835,Brompheniramine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,few,153583,DB00835,Brompheniramine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,9,153584,DB00835,Brompheniramine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,20 to 25,153585,DB00835,Brompheniramine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),d,5 to 14,153586,DB00835,Brompheniramine
,2892445,apparent volumes of distribution,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[l] / [kg],3.4 to 18.5,153587,DB00835,Brompheniramine
,2892445,total body clearances,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[ml] / [kg·min],4.4 to 32.1,153588,DB00835,Brompheniramine
,4056080,peak plasma level,"Mean kinetic variables were: peak plasma level, 99 ng/mL; time of peak, 2.4 hours postdose; elimination half-life, 10.1 hours; and apparent oral clearance, 217 mL/min.",The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056080/),[ng] / [ml],99,171481,DB00835,Brompheniramine
,4056080,time of peak,"Mean kinetic variables were: peak plasma level, 99 ng/mL; time of peak, 2.4 hours postdose; elimination half-life, 10.1 hours; and apparent oral clearance, 217 mL/min.",The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056080/),h,2.4,171482,DB00835,Brompheniramine
,4056080,elimination half-life,"Mean kinetic variables were: peak plasma level, 99 ng/mL; time of peak, 2.4 hours postdose; elimination half-life, 10.1 hours; and apparent oral clearance, 217 mL/min.",The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056080/),h,10.1,171483,DB00835,Brompheniramine
,4056080,apparent oral clearance,"Mean kinetic variables were: peak plasma level, 99 ng/mL; time of peak, 2.4 hours postdose; elimination half-life, 10.1 hours; and apparent oral clearance, 217 mL/min.",The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056080/),[ml] / [min],217,171484,DB00835,Brompheniramine
,9949311,peak brompheniramine concentration,"In 14 children, mean age 9.5 +/- 0.4 years (SEM), the peak brompheniramine concentration was 7.7 +/- 0.7 ng/mL, and the time at which peak concentrations occurred was 3.2 +/- 0.3 hours.",The clinical pharmacology of brompheniramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),[ng] / [ml],7.7,205051,DB00835,Brompheniramine
,9949311,time at which peak concentrations occurred,"In 14 children, mean age 9.5 +/- 0.4 years (SEM), the peak brompheniramine concentration was 7.7 +/- 0.7 ng/mL, and the time at which peak concentrations occurred was 3.2 +/- 0.3 hours.",The clinical pharmacology of brompheniramine in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),h,3.2,205052,DB00835,Brompheniramine
,9949311,terminal elimination half-life,"The terminal elimination half-life was 12.4 +/- 1.1 hours, and the oral clearance was 20.2 +/- 2.1 mL/min/kg.",The clinical pharmacology of brompheniramine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),h,12.4,205053,DB00835,Brompheniramine
,9949311,oral clearance,"The terminal elimination half-life was 12.4 +/- 1.1 hours, and the oral clearance was 20.2 +/- 2.1 mL/min/kg.",The clinical pharmacology of brompheniramine in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),[ml] / [kg·min],20.2,205054,DB00835,Brompheniramine
,9949311,maximum inhibition,"Compared with predose areas, the wheals and flares produced by histamine phosphate 1 mg/mL were significantly decreased from 0.5 to 30 hours and from 1 to 30 hours, respectively (P <.05), with mean maximum inhibition at 12 (52% +/- 9%) and 6 hours (72% +/- 10%), respectively.",The clinical pharmacology of brompheniramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),%,52,205055,DB00835,Brompheniramine
,9949311,maximum inhibition,"Compared with predose areas, the wheals and flares produced by histamine phosphate 1 mg/mL were significantly decreased from 0.5 to 30 hours and from 1 to 30 hours, respectively (P <.05), with mean maximum inhibition at 12 (52% +/- 9%) and 6 hours (72% +/- 10%), respectively.",The clinical pharmacology of brompheniramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949311/),%,72,205056,DB00835,Brompheniramine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,91,259299,DB00835,Brompheniramine
,1880721,Bioavailability,Bioavailability of pseudoephedrine was 91% for fed relative to fasted treatment; for brompheniramine it was 89%.,Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880721/),%,89,259300,DB00835,Brompheniramine
